JPRN-UMIN000028468
Completed
未知
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker - Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker
orst East Japan Study Group(NEJSG)0 sites60 target enrollmentStarted: August 1, 2017Last updated:
Conditionsnon-small-cell lung cancer
Overview
- Phase
- 未知
- Status
- Completed
- Sponsor
- orst East Japan Study Group(NEJSG)
- Enrollment
- 60
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Having history of immuno\-checkpoint\-inhibitor 2\.Having history of autoimune disease 3\.Having active or symptomatic interstitial lung disease 4\.With infections requiring systemic treatment 5\.Having symptomatic brain metastasis 6\.Having poorly controlled diabetes 7\.Having active liver disease 8\.Having history of severe hypersensitivity 9\.Patient judged inappropriate by the attending physician
Investigators
Similar Trials
Active, not recruiting
Phase 2
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60
Completed
Phase 2
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Studypleural mesothelioma10027412NL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
Active, not recruiting
Not Applicable
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Active, not recruiting
Phase 1
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SkiCTIS2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61
Recruiting
Phase 2
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin2024-513637-20-00Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH61